BNET Industries
Market Cap:$102.9B
Last Fiscal Year Sales:$32.9B
- Public
- FR
Dow Jones Description
Sanofi-Aventis sees the future - where disease is in the past. Formed by a 2004 merger and headquartered in Paris, France, Sanofi-Aventis (NYSE: SNY (ADR) Euronext Paris: SAN) is the third-largest pharmaceutical maker in the world. The company researches, develops, manufactures, and markets prescription drugs. Its products include Allegra, Aprovel, Eloxatin, Lovenox, Nasacort, Plavix, Taxotere, and Tritace, among others. It has over 100 compounds in development, about 40 of which are in Phase II or III clinical trials. The company has annual revenue of about A28.5 billion and employs about 100,000 people. In March 2006 the company acquired almost 25% of Zentiva NV for approximately A430 million. In 2005 the company sold its interests in Wacker-Chemie.
Number of Employees 97,181
Peer Companies
NAICS Code Drugs and Druggists' Sundries Merchant Wholesalers: 424210
Recent Events
-
Sanofi Recalls Swine Flu Vaccine for Young Children
-
Warner Chilcott Affirms Global Marketing and Collaboration Agreement With Sanofi-Aventis
-
Common heart rhythm problem on the rise in the U.S.
-
Sanofi-Aventis and Alopexx sign collaboration agreement
-
Sanofi-Aventis in research pact with CalTech
-
Generex enters insulin supply deal for Oral-lyn
-
86. Sanofi
-
Sanofi-Aventis SNY Announces Agreement with Intelliject for Novel Epinephrine Auto Injector
-
Early and Often: A Drug Investor's Dream
-
Drugmakers' Differences: Analyst's Toolkit
-
Deutsche Bank Initiates Coverage on Sanofi-Aventis SNY with a Buy
-
Big Pharma Willing to Pay for Biotech Innovation
-
Sanofi-Aventis names Spek global operations head 37 mins ago
-
Sanofi-Aventis Q3 Profit Rises; Lifts FY09 Adj. EPS Growth View; To Buy Laboratoire Oenobiol -...
-
UPDATE 3-Sanofi lifts forecast on swine flu vaccine
-
Sanofi-Aventis and Micromet to Develop New Tumour Antibody
-
Dyax Corp. Q3 2009 Earnings Call Transcript
-
Sanofi-Aventis's New JV Will Provide Entry into Chinas OTC Market
-
Mexico pushing for homegrown swine flu vaccine
News & Analysis
Filter by
sales and sanofi-aventis - All News and Analysis
Sanofi Calls Hundreds of Reps With Layoff News
BNET
- 2009-11-30
Sanofi-Aventis SNY began calling hundreds of its drug sales reps today to tell them whether they were being laid off or keeping their jobs. A company spokesperson declined to comment when asked by BNET how many reps were affected. by Jim Edwards
Sanofi Q4: No Nasty Surprises, But Viehbacher Is Focused on Sales Productivity Ratios
BNET
- 2009-02-11
There were no nasty surprises in Sanofi-Aventis's Q4 results. Yesterday, BNET had suggested that CEO Chris Viehbacher's desire to cut $1.3 billion in operating costs would fall upon sales reps, whose jobs would be axed. We also noted that, dollar for dollar (or euro for euro, in...
Sanofi-Aventis will cut 700-800 salespeople in France
- 2008-06-09
PARIS AFP — French pharmaceutical company Sanofi-Aventis said on Monday it planned to cut about a third of its sales representatives in France, or 700-800 jobs. Management "confirms the existence of overstaffing for sales representatives which is estimated at 700-800 jobs," a spokeswoman told AFP, after a report to...
French pharmaceutical group Sanofi-Aventis sees net profits rise 9 pct
- 2007-10-31
PARIS AFP — French pharmaceutical group Sanofi-Aventis raised its 2007 performance forecast Wednesday after reporting better-than-expected net earnings in the third quarter. The company said adjusted net profit rose 9.1 percent to 1.853 billion euros (2.7 billion dollars) in the third quarter from the same period last year. ...
Sanofi-Aventis slashes share earnings forecast for 2006
- 2006-09-01
PARIS AFP — French pharmaceutical group Sanofi-Aventis has slashed its 2006 earnings per share forecast from 12 percent to just two percent due to competition for its blockbuster blood-thinner Plavix from a generic drug. The revision came a day after a New York court granted the company and its US...
Sanofi fighting generic drugs tooth and nail in US courts
- 2006-08-09
PARIS AFP — The French pharmaceuticals group Sanofi-Aventis is turning to vigorous legal action to protect its best-selling drugs in the United States from cheaper generic competition. "We are sure of our patents," a spokesman for Sanofi-Aventis, the world's third largest drug group, said Wednesday. Sanofi announced it...
Novo Nordisk to grow diabetes reach
- 2006-01-01
NOVO NORDISK has announced a bid to expand its 40% share of the worldwide diabetes market via its sales reach. The Danish company already sells to 60% of U.S. doctors, but will now call on smaller medical practices to reach a new goal of 80%, according to a report published...
Sanofi-Aventis posts profit gain; share price tumbles on pipeline news
- 2005-08-31
PARIS AFP — Pharmaceutical group Sanofi-Aventis reported a 26 percent rise in second-quarter net profit from a year ago but its share price fell sharply on a mixed picture for new product prospects. The group posted second-quarter net profit of 1.553 billion euros (1.9 billion dollars), beating analysts' estimates...
Novo Nordisk's new diabetes drug approved in US
- 2005-06-17
COPENHAGEN AFP — The US Food and Drug Administration FDA has given the green light for the sale of Levemir, a long-acting insulin analogue drug for the treatment of diabetes, Danish pharmaceutical maker Novo Nordisk revealed. The drug has already been approved in 37 countries, including the European Union...
- 1
| Volume | 1,912,588 |
| Shares Outstanding | 2.6B |
| Market Cap | 102.9B |
| Year High | 40.28 |
| Year Low | 24.59 |
| Earnings Per Share | 2.21 |
| P/E Ratio | 17.6968 |
| Dividend | 1.0639 |
| Yield | 2.72 |
Industry Transcripts by Seeking Alpha
-
Neogen Corporation F2Q10 (Qtr End11/30/09) Earnings Call Transcript
on Dec 18, 2009about NEOG
-
Schiff Nutrition International, Inc. F2Q10 (Qtr End 11/30/09) Earnings Call Transcript
on Dec 17, 2009about WNI
-
Martek Biosciences Corporation F4Q09 (Qtr End 10/31/09) Earnings Call Transcript
on Dec 16, 2009about MATK
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
Glass Door
Sanofi-Aventis
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
Presented by American Express